SEC Form 4 · accession 0001209191-19-009667
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amit Sachdev
Officer — EVP, CRO
Period of report
Feb 12, 2019
Accepted (ET)
Feb 13, 2019 · 4:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Feb 11, 2019 | S | 10,568 | $179.44 | D | 64,692 | D | |
| Common StockF3,F4 | Feb 11, 2019 | S | 19,021 | $180.17 | D | 45,671 | D | |
| Common StockF3,F5 | Feb 11, 2019 | S | 5,406 | $180.85 | D | 40,265 | D | |
| Common Stock | Feb 11, 2019 | S | 100 | $182.05 | D | 40,165 | D | |
| Common Stock | holding | — | — | — | 12,215 | I | Held in Trust | |
| Common Stock | holding | — | — | — | 882 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $179.44 (range $178.61 to $179.61).
- F3Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $180.17 (range $179.64 to $180.64).
- F5Open market sales reported on this line occurred at a weighted average price of $180.85 (range $180.65 to $181.63).